[Facilitating factors and difficulties in the the implementation of sanitary surveillance of drugstores in Salvador, state of Bahia, Brazil]. / Fatores facilitadores e dificuldades no exercício da vigilância sanitária de farmácias em Salvador-Bahia.

Drugstores are the health establishments where medications are dispensed, which is why sanitary surveillance is justified as a means of intervention. The health department uses various technologies to control risk in drugstores. In this study we used the theory of the process of work in health as a benchmark in order to describe and analyze the strengths and difficulties encountered in sanitary surveillance in drugstores in Salvador. Case study methodological strategy was adopted, the analytical categories being facilitating factors and difficulties inherent to technicians, drugstore, sanitary surveillance service and the social environment. Data were collected through direct observation techniques and semi-structured interviews, and the findings were assessed using content analysis. The body of information was processed and categorized using QSR N VIVO software. It was revealed that the nature of the facilitating factors and difficulties found in surveillance activities of drugstores indicate the need for urgent change within the scope of services and the sanitary culture in the country. It also stresses the possibilities of offering a quality service for the protection of health, in a setting conducive to the development of sanitary surveillance and the process of decentralization of these actions.

[Work in health: sanitary surveillance of drugstores in Salvador (state of Bahia, Brazil)]. / Trabalho em saúde: vigilância sanitária de farmácias no município de Salvador (Bahia, Brasil).

A drugstore is an establishment of interest in health, from which medication is dispensed, namely the therapeutic technology most broadly used in the practice of medicine. The scope of this study is to describe and analyze the sanitary surveillance of drugstores. Based on the theory of working processes in healthcare, a case study was conducted on the sanitary surveillance of drugstores in Salvador (Bahia, Brazil), examining 2 analytical categories: agents and activities. Data were collected through observation, analysis of documents and interviews, and QSR N Vivo software was used for data processing. Personnel of the surveillance service were found to have varied professional and educational backgrounds, with limited experience in the sanitary surveillance of drugstores, and insufficient technical training for the performance of the tasks assigned. Deficiencies of a managerial nature were detected in the service. Its operation is primarily focused on granting drugstore licenses, prioritizing attendance to spontaneous demand, thereby configuring a technological model of intervention based on sanitary inspection. The findings revealed a need for updating the service and the adoption of technologies to enhance control of risk, given that technological evolution provides drugs that are increasingly more potent, with a concomitant rise in levels risk.

New drugs in Brazil: do they meet Brazilian public health needs?

OBJECTIVES: To describe the new drugs marketed in Brazil during the period 2000-2004, compare the description to the country's burden of disease, and suggest initiatives capable of addressing the situation from the perspective of a developing country. METHODS: Records of new drugs were surveyed in an official drug registration database. The new drugs were categorized by Anatomical Therapeutic Chemical classification, indication, and innovation, and compared with the needs of the country's burden of disease. Data on the morbidity and mortality rates of selected diseases (diabetes, Hansen's disease, hypertension, tuberculosis) were retrieved from official documents and the literature. RESULTS: During the period investigated, 109 new drugs were launched. Most were general anti-infectives for systemic use (19), followed by antineoplastic and immunomodulating agents (16). The number of new drugs launched in 2004 was roughly one-third that of 2000. Of 65 new drugs, only one-third can be classified as innovative. Most new drugs were intended to treat noninfectious diseases that typically affect developed countries, diseases that constitute only a fraction of the country's challenges. CONCLUSIONS: A mismatch occurs between public health needs and the new drugs launched on the Brazilian market. Not only did the number of new drugs decrease in the study period, but only a few were actually new in therapeutic terms. Developing countries must acquire expertise in research and development to strengthen their capacity to innovate and produce the drugs they need.